Toward a chemotherapy and allo-HSCT free future: the evolution of treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia
The treatment landscape for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has undergone a profound transformation over the past two decades. The integration of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has shifted the paradig…